+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Immune Checkpoint Inhibitors for Cancer Market by Indication (Bladder Cancer, Head and Neck Cancer, Melanoma), Mechanism of Action (Ctla4 Inhibitor, Pd1 Inhibitor, Pdl1 Inhibitor), Treatment Modality, Therapy Line, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6118402
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The advent of immune checkpoint inhibitors marked a paradigm shift in cancer therapeutics, heralding a new era in which the body’s own immune system is harnessed to recognize and eliminate malignant cells. Early clinical successes in melanoma and lung carcinoma validated the potential of CTLA-4 and PD-1 blockade to induce durable responses in patients who had previously exhausted conventional treatment options. Since then, expansion into additional tumor types and lines of therapy has accelerated, underscoring the versatility of these agents and reinforcing their status as cornerstones of modern oncology.

Mechanistically, checkpoint inhibitors release inhibitory signals that cancer cells exploit to evade immune surveillance, enabling T-cell activation and tumor eradication. This fundamental understanding has catalyzed a rich pipeline of novel targets and combination strategies designed to amplify response rates, overcome resistance, and extend benefit to a broader patient population. As the landscape evolves, real-world evidence and biomarker-driven approaches are playing a pivotal role in refining patient selection and optimizing clinical outcomes.

In this executive summary, the multifaceted impact of checkpoint blockade on therapeutic protocols, clinical development, and healthcare delivery is examined. By exploring transformative shifts, segmentation insights, regional dynamics, corporate strategies, and actionable recommendations, this document offers a comprehensive overview of the current state of immune checkpoint inhibitors and illuminates pathways for sustained innovation and growth in the oncology sector.

Evolution of Checkpoint Blockade Strategies Bridging Monotherapy and Combination Regimens to Redefine the Standard of Cancer Care Across Multiple Indications

Over the past decade, checkpoint blockade has transitioned from pioneering single-agent therapies to a complex matrix of monotherapies and multidimensional combination regimens. Initial approvals for CTLA-4 and PD-1 inhibitors in advanced melanoma set a precedent for durable responses. Rapid label expansions followed, extending indications into non-small cell lung cancer, renal cell carcinoma, head and neck squamous cell carcinomas, and bladder cancer. Clinicians gained confidence in employing these agents across first, second, and subsequent treatment lines, resulting in a reshaped oncology practice environment that prioritizes immune activation over cytotoxicity.

Subsequent research demonstrated that pairing checkpoint inhibitors with traditional cytotoxic chemotherapy or targeted biologics enhances antitumor activity. Chemotherapy combinations have improved response rates by modulating immunogenic cell death, while immunotherapy duo regimens exploit complementary mechanisms to broaden the scope of immune engagement. Simultaneously, pairing PD-1/PD-L1 agents with targeted therapies such as VEGF inhibitors or PARP inhibitors has underscored the potential of rationally designed combinations to circumvent tumor resistance pathways. These advances have bolstered overall survival trends and reinvigorated clinical trial designs focusing on adaptive treatment schemas.

Looking ahead, the field is witnessing the emergence of novel immunomodulatory targets including LAG-3, TIGIT, and TIM-3, along with bispecific constructs and personalized vaccine strategies. Real-world evidence platforms and advanced biomarker analyses are refining patient stratification, thereby enhancing trial efficiency and regulatory alignment. Through these transformative shifts, checkpoint blockade continues to redefine cancer care, offering new hope for patients across a spectrum of malignancies.

Assessing the Ripple Effects of United States Tariff Adjustments in 2025 on Immune Checkpoint Therapy Accessibility and Commercial Dynamics

The introduction of revised tariff measures in 2025 has prompted pharmaceutical manufacturers and healthcare providers to reexamine their supply chain architectures and pricing frameworks. As specific components and active pharmaceutical ingredients for checkpoint inhibitors are subjected to new import duties, production costs have incrementally increased, compelling stakeholders to recalibrate sourcing strategies. These adjustments have underscored vulnerabilities in global manufacturing networks, particularly in regions where key intermediates are concentrated.

Consequently, some developers have expedited investments in domestic production facilities or diversified regional manufacturing partnerships to mitigate exposure to tariff volatility. Such realignment aims to preserve cost efficiencies and maintain the agility required for rapid scale-up of clinical and commercial operations. At the same time, procurement teams within hospitals and specialty oncology clinics are engaging in more rigorous contract negotiations to secure favorable terms, with an emphasis on long-term supply commitments.

In response to these complexities, industry leaders are exploring tiered pricing models and co-development agreements that accommodate fluctuating duty structures. By fostering collaborative relationships with regulatory bodies and customs authorities, companies are seeking to streamline clearance processes and avoid potential delays. Although tariff revisions introduce short-term cost pressures, they also catalyze strategic dialogue around resilient manufacturing footprints and innovative commercial frameworks, laying the groundwork for sustainable market growth.

Diving into Multi-Dimensional Market Segmentation to Uncover Personalized Immuno-Oncology Trends by Indication Mechanism and Therapeutic Settings

A comprehensive segmentation framework reveals critical nuances in the adoption and utilization of checkpoint inhibitors across multiple clinical dimensions. Based on indication, the landscape encompasses five major tumor types: bladder cancer, head and neck cancer, melanoma, non-small cell lung cancer further delineated into non-squamous and squamous subtypes, and renal cell carcinoma divided between clear cell and non-clear cell variants. This granularity enables a targeted assessment of efficacy profiles and unmet needs within each histological cohort, guiding strategic prioritization for future clinical development.

Examining mechanism of action, the market is categorized into CTLA-4 inhibitors, PD-1 inhibitors, and PD-L1 inhibitors. Within the PD-1 segment, agents such as cemiplimab, dostarlimab, nivolumab and pembrolizumab each demonstrate distinct pharmacodynamic and safety characteristics that influence prescribing patterns. This separation underscores the importance of head-to-head comparative research and real-world evidence studies to inform differentiation and lifecycle management strategies.

Treatment modality segmentation distinguishes monotherapy from combination therapy. Combination approaches span chemotherapy combinations, immunotherapy duos, and targeted therapy pairings, each designed to synergize with checkpoint blockade and improve response durability. Therapy line stratification further refines the analysis by separating first-line, second-line, and third-line and beyond settings, reflecting how resistance mechanisms and patient health status drive regimen selection. Finally, end-user segmentation contrasts the purchasing behavior and clinical workflows of hospitals with those of specialty oncology clinics. Incorporating these five interlocking layers of segmentation delivers a holistic view of the commercial landscape, ensuring that innovation efforts align precisely with evolving patient populations and care delivery models.

Regional Variations in Checkpoint Inhibitor Adoption Reflecting Diverse Healthcare Infrastructure and Reimbursement Models Around the Globe

In the Americas, well-established reimbursement pathways and robust clinical trial networks have accelerated the integration of checkpoint inhibitors into standard-of-care protocols. Extensive real-world data harvesting and patient assistance programs have addressed affordability concerns, while centralized regulatory frameworks have facilitated expedited approvals for novel indications. Collaborative initiatives between public and private sectors underpin continued innovation, as evidenced by a high volume of ongoing combination trials and biomarker research programs.

Across Europe, the Middle East and Africa, heterogeneous healthcare systems and divergent funding mechanisms have led to varied levels of market penetration. While several European countries exhibit early adoption driven by national health technology assessments, other regions face challenges in securing formulary inclusion amid competing budget priorities. Nonetheless, multinational partnerships and regional consortiums are emerging to standardize clinical guidelines and enhance access to cost-effective immunotherapies, particularly in resource constrained environments.

Within Asia-Pacific, a rapidly evolving regulatory landscape and rising investment in domestic biotechnology initiatives are transforming the immuno-oncology arena. Authorities are increasingly aligning approval processes with global standards, enabling local manufacturers to participate in technology transfer programs and co-development ventures. Simultaneously, expanding cancer screening programs and growing awareness among healthcare professionals are fueling demand for checkpoint inhibitors, creating fertile ground for tailored market entry strategies and region-specific clinical research collaborations.

Competitive Landscape Overview of Leading Immunotherapy Developers Driving Innovation in Checkpoint Blockade Research and Commercialization Pathways

Several global biopharmaceutical organizations have emerged as pivotal architects of the checkpoint inhibitor ecosystem. Pioneering efforts by one developer with its first CTLA-4 targeted antibody established a proof of concept for immune checkpoint therapy and seeded a pipeline that has since been extended through strategic collaborations. Another market leader has set benchmark standards with PD-1 inhibitors, securing approvals across a spectrum of tumor types and fostering label expansions through robust phase III studies. This actor’s emphasis on extensive post-approval real-world evidence generation and patient support initiatives has reinforced its competitive position.

Other notable players have carved out differentiation through targeted PD-L1 compounds that leverage companion diagnostics to enhance patient selection and maximize therapeutic benefit. Partnerships between global pharma houses and regional biotech firms have unlocked novel combination regimens, integrating antiangiogenic agents or oncolytic viruses to amplify immune responses. Emerging biotechnology companies are advancing second-generation checkpoint modalities and bispecific platforms, injecting fresh momentum into clinical pipelines. Collectively, these diverse corporate strategies-from label diversification and geographic expansion to precision medicine approaches-are shaping the evolution of immune checkpoint blockade and setting the stage for future breakthroughs in oncology care.

Strategic Recommendations for Biotech and Pharma Stakeholders to Accelerate Immune Checkpoint Program Development and Market Penetration

Organizations seeking to solidify their position in the checkpoint inhibition arena should prioritize a multi-pronged approach that balances scientific innovation with commercial execution. First, investing in advanced biomarker discovery and validation will streamline patient selection, reduce trial attrition rates, and reinforce payer value propositions. By collaborating closely with diagnostic developers and leveraging novel omics technologies, teams can identify predictive markers that differentiate responders from non-responders early in development.

Second, designing adaptive clinical trial frameworks that integrate interim real-world evidence can optimize resource allocation and support more informed go/no-go decisions. Such models enable seamless transitions between monotherapy and combination cohorts, accelerating the evaluation of synergistic regimens. Third, strengthening supply chain resilience by diversifying manufacturing sites and sourcing critical raw materials from geographically dispersed partners will mitigate the impact of policy changes and trade fluctuations.

Fourth, engaging proactively with regulatory agencies to establish harmonized approval pathways and adaptive licensing agreements can reduce time to market and align evidence requirements across key geographies. Finally, fostering value-based contracting arrangements with payers and healthcare systems-anchored on outcome metrics and risk-sharing models-will enhance market access and ensure sustainable adoption of checkpoint therapeutics. Collectively, these actionable strategies will help biotech and pharmaceutical stakeholders navigate a complex market landscape and realize the full potential of immune checkpoint inhibitors.

Rigorous Methodological Framework Combining Primary Clinical Expert Interviews and Comprehensive Secondary Data to Ensure Analytical Depth and Precision

The insights presented in this report are derived from a structured, transparent research methodology designed to maximize reliability and depth. Primary research consisted of in-depth interviews with key opinion leaders, including oncologists, clinical researchers, health economists, and payer representatives. These discussions provided firsthand perspectives on clinical trial design, real-world utilization patterns, reimbursement challenges, and emerging therapeutic innovations. Engagements were conducted across multiple regions to capture diverse healthcare environments and regulatory nuances.

Secondary research complemented these qualitative inputs by systematically reviewing peer-reviewed journals, clinical trial registries, patent filings, regulatory agency publications, company press releases, and treatment guidelines. Quantitative data were extracted using validated data capture protocols, with cross-referencing to eliminate discrepancies and ensure consistency. A proprietary data triangulation process was employed to reconcile insights from primary and secondary sources, enhancing the robustness of key findings.

Analytical frameworks incorporated segmentation analyses, competitive benchmarking, and scenario mapping to explore potential market evolution under varying clinical, regulatory, and economic conditions. Rigorous quality control measures, including peer review and editorial validation, were applied at each stage of the research process. This methodological approach ensures that conclusions and recommendations reflect both the current state of immune checkpoint inhibitor development and the dynamic forces shaping the future of oncology care.

Concluding Reflections on the Transformative Potential of Checkpoint Inhibitors and Imperatives for Sustained Innovation in Oncology

Immune checkpoint inhibitors have undeniably redefined the therapeutic landscape in oncology by unlocking durable antitumor responses and fostering a deeper understanding of tumor-immune system interactions. The rapid proliferation of indications, coupled with evolving combination strategies and precision medicine applications, underscores the transformative impact of these agents on patient care. Yet, challenges remain in addressing primary and acquired resistance, optimizing long-term safety, and ensuring broad access across diverse healthcare settings.

Looking forward, sustained innovation will hinge on a collaborative ecosystem that integrates scientific discovery, clinical development, and stakeholder alignment. Investments in next-generation immune modulators, advanced diagnostic platforms, and digital health solutions are essential to augment current treatment paradigms. Moreover, adaptive regulatory frameworks and value-based access models will play a decisive role in bridging the gap between clinical promise and real-world adoption.

By synthesizing segmentation insights, regional dynamics, corporate strategies, and actionable recommendations, this summary illuminates pathways for accelerating progress in immune checkpoint therapy. As researchers, clinicians, and industry leaders unite around shared objectives, the potential to further improve survival outcomes and quality of life for patients with cancer will expand, charting a new course in the battle against this complex and heterogeneous disease.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Indication
    • Bladder Cancer
    • Head And Neck Cancer
    • Melanoma
    • Non Small Cell Lung Cancer
      • Non Squamous
      • Squamous
    • Renal Cell Carcinoma
      • Clear Cell Rcc
      • Non Clear Cell Rcc
  • Mechanism Of Action
    • Ctla4 Inhibitor
    • Pd1 Inhibitor
      • Cemiplimab
      • Dostarlimab
      • Nivolumab
      • Pembrolizumab
    • Pdl1 Inhibitor
  • Treatment Modality
    • Combination Therapy
      • Chemotherapy Combination
      • Immunotherapy Combination
      • Targeted Therapy Combination
    • Monotherapy
  • Therapy Line
    • First Line
    • Second Line
    • Third Line And Beyond
  • End User
    • Hospitals
    • Specialty Oncology Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:

  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Roche Holding AG
  • AstraZeneca PLC
  • Pfizer Inc.
  • Merck KGaA
  • Sanofi S.A.
  • Regeneron Pharmaceuticals, Inc.
  • BeiGene, Ltd.
  • GlaxoSmithKline plc

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of next-generation bispecific checkpoint inhibitor antibodies targeting dual immune pathways
5.2. Integration of PD-1 inhibitors with novel cancer vaccines to enhance immunogenic response
5.3. Adoption of personalized combination therapies combining CTLA-4 and PD-L1 inhibitors in solid tumors
5.4. Development of small molecule checkpoint inhibitors overcoming resistance to monoclonal antibodies
5.5. Advances in biomarker-driven patient stratification to optimize immune checkpoint therapy efficacy
5.6. Growth of domestic production capabilities for biosimilar checkpoint inhibitors in emerging markets
5.7. Expansion of clinical trials evaluating checkpoint inhibitors in earlier lines of treatment and adjuvant settings
5.8. Surge in collaborations between biotech startups and big pharma for next generation checkpoint therapies
5.9. Advances in delivery technologies such as nanoparticles and oncolytic viruses for targeted checkpoint inhibitors
5.10. Incorporation of artificial intelligence in predicting patient response and resistance to checkpoint inhibitors
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Immune Checkpoint Inhibitors for Cancer Market, by Indication
8.1. Introduction
8.2. Bladder Cancer
8.3. Head And Neck Cancer
8.4. Melanoma
8.5. Non Small Cell Lung Cancer
8.5.1. Non Squamous
8.5.2. Squamous
8.6. Renal Cell Carcinoma
8.6.1. Clear Cell Rcc
8.6.2. Non Clear Cell Rcc
9. Immune Checkpoint Inhibitors for Cancer Market, by Mechanism Of Action
9.1. Introduction
9.2. Ctla4 Inhibitor
9.3. Pd1 Inhibitor
9.3.1. Cemiplimab
9.3.2. Dostarlimab
9.3.3. Nivolumab
9.3.4. Pembrolizumab
9.4. Pdl1 Inhibitor
10. Immune Checkpoint Inhibitors for Cancer Market, by Treatment Modality
10.1. Introduction
10.2. Combination Therapy
10.2.1. Chemotherapy Combination
10.2.2. Immunotherapy Combination
10.2.3. Targeted Therapy Combination
10.3. Monotherapy
11. Immune Checkpoint Inhibitors for Cancer Market, by Therapy Line
11.1. Introduction
11.2. First Line
11.3. Second Line
11.4. Third Line And Beyond
12. Immune Checkpoint Inhibitors for Cancer Market, by End User
12.1. Introduction
12.2. Hospitals
12.3. Specialty Oncology Clinics
13. Americas Immune Checkpoint Inhibitors for Cancer Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Immune Checkpoint Inhibitors for Cancer Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Immune Checkpoint Inhibitors for Cancer Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Merck & Co., Inc.
16.3.2. Bristol-Myers Squibb Company
16.3.3. Roche Holding AG
16.3.4. AstraZeneca PLC
16.3.5. Pfizer Inc.
16.3.6. Merck KGaA
16.3.7. Sanofi S.A.
16.3.8. Regeneron Pharmaceuticals, Inc.
16.3.9. BeiGene, Ltd.
16.3.10. GlaxoSmithKline plc
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET: RESEARCHAI
FIGURE 26. IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET: RESEARCHSTATISTICS
FIGURE 27. IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET: RESEARCHCONTACTS
FIGURE 28. IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY BLADDER CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MELANOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SQUAMOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SQUAMOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY SQUAMOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY SQUAMOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY CLEAR CELL RCC, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY CLEAR CELL RCC, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON CLEAR CELL RCC, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON CLEAR CELL RCC, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY CTLA4 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY CTLA4 INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY DOSTARLIMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY DOSTARLIMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NIVOLUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PDL1 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PDL1 INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY CHEMOTHERAPY COMBINATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY CHEMOTHERAPY COMBINATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY IMMUNOTHERAPY COMBINATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY IMMUNOTHERAPY COMBINATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TARGETED THERAPY COMBINATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TARGETED THERAPY COMBINATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY SPECIALTY ONCOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY SPECIALTY ONCOLOGY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 119. CANADA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 120. CANADA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 121. CANADA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 122. CANADA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 123. CANADA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 124. CANADA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 125. CANADA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 126. CANADA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 127. CANADA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 128. CANADA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 129. CANADA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 130. CANADA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 131. CANADA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 132. CANADA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 133. CANADA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 134. CANADA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 135. CANADA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 136. CANADA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 137. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 138. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 139. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 140. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 141. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 142. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 143. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 144. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 145. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 146. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 147. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 148. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 149. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 150. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 151. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 152. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 153. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 230. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 231. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 232. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 233. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 234. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 235. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 236. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 237. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 238. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 239. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 240. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 241. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 242. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 243. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 244. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 245. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 248. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 249. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 250. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 251. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 252. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 253. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 254. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 255. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 256. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 257. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 258. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 259. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 260. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 261. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 262. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 263. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2024 (USD MILLION)
T

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Immune Checkpoint Inhibitors for Cancer market report include:
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Roche Holding AG
  • AstraZeneca PLC
  • Pfizer Inc.
  • Merck KGaA
  • Sanofi S.A.
  • Regeneron Pharmaceuticals, Inc.
  • BeiGene, Ltd.
  • GlaxoSmithKline plc